Provided by Tiger Trade Technology Pte. Ltd.

First Trust Nasdaq Pharmaceuticals ETF

40.73
-0.0900-0.22%
Post-market: 40.730.00000.00%19:30 EDT
Volume:53.73K
Turnover:2.19M
Market Cap:1.04B
PE:- -
High:40.88
Open:40.82
Low:40.53
Close:40.82
52wk High:43.52
52wk Low:28.77
Shares:25.65M
Float Shares:25.65M
Volume Ratio:0.06
T/O Rate:0.21%
Dividend:0.29
Dividend Rate:0.71%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

Jefferies Adjusts Price Target on Merck & Co to $177 From $175, Keeps Buy Rating

MT Newswires Live
·
Oct 01

InflaRx Appoints Gabriela Alperovich as SVP, Global Head of Clinical Development

Reuters
·
Oct 01

Coty Names Kara Langan General Manager, U.S. Consumer Beauty Division

Reuters
·
Oct 01

Lilly Says Foundayo Cuts Predicted 10-Year Type 2 Diabetes Risk 57% in Attain-1 Post-Hoc Analysis

Reuters
·
Oct 01

Iovance Biotherapeutics Names Noah Berkowitz Chief Medical Officer

Reuters
·
Oct 01

Eli Lilly - Foundayo 17.2 Mg Associated with 57% Reduction in Diabetes Risk, 18% in Cardiovascular Risk Versus Placebo

Reuters
·
Oct 01

Eli Lilly - Foundayo Associated with Reduced Predicted Long-Term Risk of Type 2 Diabetes and Cardiovascular Disease

THOMSON REUTERS
·
Oct 01

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

THOMSON REUTERS
·
Oct 01

Merck Schedules Third-Quarter Sales and Earnings Conference Call with Investors and Analysts

Reuters
·
Oct 01

Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow

Simply Wall St.
·
Oct 01

Sanofi’s Regeneron Fix Requires Extra Shot of M&A

Reuters
·
Oct 01

Bayer Names Christoph Koenen Chief Medical Officer

Reuters
·
Oct 01

Faron Pharmaceuticals Doses First Patient in Phase 1/2 BLAZE Trial of Bexmarilimab Plus Bristol Myers’ Opdivo in PD-1-Resistant Solid Tumors

Reuters
·
Oct 01

Merck & Co Inc : Jefferies Raises Target Price to $177 from $175

THOMSON REUTERS
·
Oct 01

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Oct 01

The Next Frontier for Obesity Drugs Isn't How Much Weight You Lose, but What Kind

Dow Jones
·
Oct 01

Eli Lilly Says Foundayo Drug Helped Patients Lose Weight in Phase 3 Trial

Dow Jones
·
Oct 01

Eli Lilly’s Foundayo shows cardiovascular safety in type 2 diabetes study

TIPRANKS
·
Oct 01

Lilly's Oral Glp-1, Foundayo (Orforglipron), Demonstrated Cardiovascular Safety Alongside Sustained A1c Reduction and Weight Loss in Its Largest and Longest Type 2 Diabetes Study

THOMSON REUTERS
·
Oct 01

Eli Lilly - Achieve-4: Foundayo Shows 16% Lower Mace-4 and 23% Lower Mace-3 Risk vs Insulin Glargine

THOMSON REUTERS
·
Oct 01